front-page.php

YURiA-PHARM is a Ukrainian pharmaceutical group of companies heading out into the world

90%

profits
reinvest

+20%

targets growth
annually

20+

new products
annually

600+

registration
certificates

41+

operate in countries
around the world

25%

is part of the
exports
July 9 is the anniversary of the founding of YURiA-PHARM
About the company

July 9 is the anniversary of the founding of YURiA-PHARM

July 9 is the anniversary of the founding of the Ukrainian pharmaceutical group YURіA-PHARM. It was thirty-two years ago that the business was founded, which grew, developed and changed together with Ukraine. During this time, we have experienced many trials, but we have never had to work during a war. War. In the early days,…

Read more
War in Ukraine

February 24, 2022 Сhronicle of the war

The war mobilized and rallied domestic pharmaceutical companies to selfless work 24/7. We all understand what an important duty is entrusted to us: to support the defense capability of our country, providing the health care system and military medicine with the necessary medicines. Today, YURіА-PHARM has focused on two directions – production and distribution. Production….

Read more
Growth

YURіA-PHARM Group considers localising vaccine production in Ukraine

Dmytro Derkach, CEO of YURіA-PHARM Group, told Interfax-Ukraine that the company is working to make vaccines available to Ukrainians, including the COVID-19 vaccine. “Five years ago, construction was started of a new 25,000-square-metre plant in Cherkasy for high-tech aseptic and biotechnological production. The operating departments of the new production facility will be up and running…

Read more

Key areas of R&D

  • Adaptation, development and scaling of technologies for the production of biopharmaceutical APIs and drugs based on them
  • Development of products based on hyaluronic acid
  • Development of Active Pharmaceutical Ingredients
  • Development and implementation in manufacturing of hospital drugs and medical devices
Find out more about R&D
Umerox<sup>®</sup> Ingal
For Partners
Products

Umerox® Ingal

Umerox® Ingal is an individual device designed for inhalation of methoxyflurane. Methoxyflurane, solution for inhalation, 2 ml administered through the Yumerox® Ingal inhaler is a fast-acting, inhalable and non-narcotic analgesic. Indications for the use of Methoxyflurane are emergency relief of moderate to severe pain in adult patients with trauma who are conscious. Аnesthesia for short-term treatment…